Nov 2012

Home >> Clinical Trials News Archive >> 2012 >> Nov 2012
FDA has issued the draft guidance, "IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed." 
Israel 2nd in world in adults with academic degrees. According to a new report by the Organization for Economic Cooperation and Development’s 2012 Education at a Glance, 46% of Israelis have higher education degrees. The report analyzed the education systems of the 34 OECD member countries. Canada is in first place at 51%. 
Global Cleantech 100 Index: Israel “The Stand-Out Country”. The prestigious research firm Cleantech Group has just published its fourth annual Global Cleantech 100 list, which lists the upcoming private companies to watch in the global cleantech arena. Israel, which ranked as the #2 country in the 2012 Global Cleantech Innovation Index, is in a unique leadership position, with companies that are both innovative and market-minded.
Teva 5th Largest Biotech Company Worldwide. Genetic Engineering & Biotechnology News recently released their analysis of the top 25 biotech companies worldwide based on market capitalization at the end of the 2nd quarter of this year. TEVA, with a market cap of $34.23 billion, was named 5th largest. The first four companies noted are novo Nordisk, Amgen, Gilead Sciences and Biogen Idec.
Tel Aviv among 25 most innovative cities. Israeli metropolis nominated by Wall Street Journal for City of the Year contest alongside New York, London. Tel Aviv has been nominated as one of the world's most innovative cities in Wall Street Journal magazine's City of the Year contest, sponsored by Citibank.
Keeping potential patients connected to trials. Industry efforts to address patient recruitment challenges have widely overlooked an important issue: When patients volunteer for a clinical trial but are disqualified during the screening process, for any number of reasons, many are disappointed and disillusioned, and give up on participation altogether. Rrecent initiatives have emerged that allow companies to share more information about trials actively enrolling and redirect volunteers who don’t qualify for one study into other studies.